Imricor Submits Third of Four FDA Modules Ahead of 2026 US Approval Target
Imricor Medical Systems has submitted Module 3 of its four-module Premarket Approval (PMA) application to the US Food and Drug Administration (FDA), covering non-clinical bench testing results for three devices: the Vision-MR Ablation Catheter 2.0, RF-5000 Ablation Generator, and RF-5000 Irrigation Tubing Set. The submission positions the company closer to US regulatory approval for its interventional cardiac ablation technology designed to treat type I atrial flutter under real-time magnetic resonance (MR) guidance.
Imricor advances towards US market entry with third FDA module submission
The Module 3 submission represents the third of four modules required under Imricor’s modular PMA pathway, a regulatory strategy designed to streamline the approval process by submitting and reviewing components serially rather than in a single filing. Imricor is executing a modular review process with the FDA, whereby modules covering various aspects of the Company’s products are submitted and reviewed serially, with the goal of achieving a more streamlined review process.
The three devices covered in the submission form the core therapy delivery platform for Imricor’s interventional MR cardiac ablation system. The Vision-MR Ablation Catheter 2.0 delivers radiofrequency energy to ablate cardiac tissue, whilst the RF-5000 Ablation Generator controls energy delivery parameters, and the RF-5000 Irrigation Tubing Set provides cooling during the ablation procedure. The target indication is type I atrial flutter, a cardiac arrhythmia affecting millions of patients globally.
With three of four modules now submitted, Imricor’s regulatory timeline remains on track for FDA approval and clearance of its platform products in 2026, according to company guidance. The US represents the company’s largest addressable market opportunity, significantly exceeding the European Union, Saudi Arabia, and New Zealand markets where Imricor’s products currently hold regulatory approval.
When big ASX news breaks, our subscribers know first
What is a modular PMA review and why does it matter?
The FDA’s PMA pathway is mandated for Class III medical devices that present the highest level of regulatory scrutiny due to their life-sustaining or life-supporting nature. Unlike the 510(k) pathway, which clears devices by demonstrating substantial equivalence to existing approved products, PMA requires manufacturers to provide comprehensive clinical evidence proving safety and efficacy for novel devices without predicate comparisons.
Imricor’s modular approach allows the company to submit components covering different aspects of the device platform separately. Each module undergoes FDA review upon submission, rather than waiting for a complete filing. This serial review process can reduce the time between final submission and approval decision, as FDA reviewers assess technical, manufacturing, and clinical data incrementally.
The modular PMA structure requires four distinct submissions:
- Module 1: Administrative information and regulatory correspondence
- Module 2: Device description, specifications, and manufacturing processes
- Module 3: Non-clinical bench testing and performance validation
- Module 4: Clinical trial data demonstrating safety and efficacy in human subjects
By contrast, a 510(k) clearance relies on demonstrating that a new device is substantially equivalent to an existing legally marketed device. This pathway typically requires less clinical evidence and shorter review timelines but is unavailable for novel technologies like Imricor’s MR-compatible ablation system, which has no predicate device.
Scope of Module 3 non-clinical bench testing
The Module 3 submission exceeds 10,000 pages and documents comprehensive testing across multiple engineering and quality disciplines. The testing programme covers eight distinct categories that validate the devices’ performance, safety, and compatibility within the magnetic resonance environment:
- Product performance
- Sterile shelf life
- Packaging integrity
- Software testing
- Electrical safety
- Electromagnetic compatibility
- Magnetic resonance safety
- Usability
This submission represents years of design, manufacturing, and testing work spanning Imricor’s Regulatory, Design Assurance, Quality, R&D, and Operations teams. Magnetic resonance safety testing is particularly critical, as conventional cardiac ablation devices use ferromagnetic materials that are incompatible with MR scanners. Imricor’s platform must demonstrate it can operate safely within the powerful magnetic fields of clinical MR systems whilst maintaining precise functionality for cardiac procedures.
The usability testing component addresses human factors engineering, ensuring physicians can effectively operate the system during time-sensitive cardiac procedures. This testing typically involves clinical user evaluations and failure mode analysis to identify and mitigate potential use errors.
Remaining pathway to US approval
Module 4, the clinical module, represents the final submission required to complete Imricor’s PMA application. This module will comprise data from the company’s VISABL-AFL trial, which is described as being in the later stages of completion. The trial evaluates the Vision-MR Ablation Catheter’s safety and efficacy for treating type I atrial flutter under real-time MR guidance.
The VISABL-AFL trial site expansion to a fourth US location, including Oklahoma Heart Institute where procedures commenced in March 2025, was designed to compress the enrolment timeline and reduce execution risk ahead of the Module 4 clinical data submission.
| Module | Content | Status |
|---|---|---|
| 1 | Administrative | Submitted |
| 2 | Device description | Submitted |
| 3 | Non-clinical bench testing | Submitted (June 2026) |
| 4 | Clinical data (VISABL-AFL) | Pending |
Management has stated its expectation for FDA approval and clearance of platform products in the US this year. This timeline positions VISABL-AFL trial completion as the critical near-term catalyst, with Module 4 submission triggering the final phase of FDA review. Once all modules are submitted, the FDA conducts an integrated assessment of the complete PMA package before rendering an approval decision.
The modular approach has allowed Imricor to advance through technical and manufacturing reviews whilst clinical trial enrolment and follow-up continue. This parallel progression aims to compress the overall regulatory timeline compared to traditional single-submission PMA pathways.
Parallel 510(k) clearances building US product portfolio
Concurrently with the PMA process, Imricor is pursuing multiple 510(k) clearances for complementary devices that form part of its interventional MR platform. Three products have already received FDA 510(k) clearance:
- NorthStar Mapping System – capital equipment for electrophysiology mapping
- Vision-MR Diagnostic Catheter – single-use diagnostic device for cardiac procedures
- Vision-MR Diagnostic Catheter Cable – connectivity component for the diagnostic catheter
So far, three products have received 510(k) clearance: NorthStar, Vision-MR Diagnostic Catheter, and Vision-MR Diagnostic Catheter Cable.
The dual regulatory strategy (PMA for the therapeutic ablation system, 510(k) for diagnostic and ancillary devices) creates a phased commercialisation pathway.
Management commentary
Steve Wedan, Executive Chair, President and CEO
“This is another significant regulatory milestone for Imricor. The submission, which exceeds ten thousand pages, represents years of design, manufacturing, and testing of the most sophisticated interventional MR tools in existence. It is a tremendous effort that spans not only our Regulatory group, but also our Design Assurance, Quality, R&D, and Operations groups. These teams continue to keep us on track for FDA approval and clearance of our platform products in the US this year.”
The next major ASX story will hit our subscribers first
What this means for Imricor’s investment case
Imricor’s products currently hold regulatory approval in the European Union, Saudi Arabia, and New Zealand, but the US represents a significantly larger addressable market for cardiac electrophysiology devices.
The company is executing on its stated 2026 FDA approval timeline, with three of four PMA modules now submitted and reviewed by the FDA. This regulatory progression reduces a key investment risk, as each accepted module de-risks technical, manufacturing, and design aspects of the platform ahead of clinical data review.
Regulatory execution demonstrates Imricor’s ability to navigate the most stringent FDA pathway whilst maintaining product development timelines. The forward catalyst remains Module 4 submission following VISABL-AFL trial completion, which will trigger the integrated PMA review and position the company for a binary approval decision in the coming months. US market access represents the primary near-term value driver for Imricor shareholders.
Beyond atrial flutter, the VISABL-VT trial expansion into a third European site signals Imricor’s longer-term pipeline ambition: ventricular tachycardia ablation represents a substantially larger addressable market and would extend the MRI-guided platform into one of the most complex and high-risk cardiac arrhythmia indications.
Want the Next MedTech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment market-moving announcements hit the ASX.